{"url_path":"/sec/vtgn/10-k/2026/body","section_key":"body","section_title":"Body","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001628280-26-043271-index.html","accession_number":"0001628280-26-043271","cik":"0001411685","ticker":"VTGN","issuer_name":"Vistagen Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001628280-26-043271-index.html","primary_entity_key":"0001411685","primary_entity_name":"Vistagen Therapeutics, Inc."},"word_count":70,"has_tables":false,"body_markdown":"EX-23.1\n3\nvtgn-exx231x20260615.htm\nEX-23.1\n\nDocument\n\n        \n\nConsent of Independent Registered Public Accounting Firm\n\nWe consent to the incorporation by reference in the registration statements (Nos. 333-277041 and 333-270232) on Form S-3 and registration statements (Nos. 333-280246, 333-259779, 333-234026, 333-223556, and 333-208354) on Form S-8 of our reports dated June 15, 2026, with respect to the consolidated financial statements of Vistagen Therapeutics, Inc.\n\n/s/ KPMG LLP\n\nSan Francisco, California\n\nJune 15, 2026"}